生物工程化iPSC来源巨核细胞用于检测血小板特异性患者同种抗体
研究通过基因编辑构建HLA I类阴性的O型iPSC系,将内源性HPA-3a表位转为HPA-3b、HPA-9a转为HPA-9b,并分化为CD41+/CD42b+巨核细胞。流式检测显示HPA-3a阳性巨核细胞特异反应于HPA-3a患者血清,HPA-3b巨核细胞失去对HPA-3a血清的反应性并获得对HPA-3b血清的反应性;表达HPA-9b的巨核细胞可特异检出常规技术无法检测的疑似抗HPA-9b患者样本。
要点
- 基因编辑iPSC来源巨核细胞可表达完整同种抗原表位。
- HPA-3b巨核细胞可区分HPA-3a与HPA-3b同种抗体。
- HPA-9b巨核细胞可检出常规方法阴性的疑似抗HPA-9b样本。
核心结论
- 表达完整纯合糖蛋白同种抗原的iPSC来源巨核细胞可增强对稀有HPA特异性同种抗体的检测。
研究设计与样本
- 研究构建了一系列HLA I类阴性血型O型iPSC系,经基因编辑将内源性HPA-3a表位转为HPA-3b、HPA-9a转为HPA-9b。
主要发现
- HPA-3a阳性巨核细胞特异反应于HPA-3a患者血清,HPA-3b巨核细胞失去对HPA-3a血清的反应性并获得对HPA-3b血清的反应性。
- 表达HPA-9b的巨核细胞特异反应于常规技术无法检测的疑似抗HPA-9b患者样本。
临床怎么用
- 该细胞平台有望用于检测临床重要且罕见的HPA特异性同种抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human platelet membrane glycoprotein polymorphisms can be immunogenic in man and are frequently the cause of clinically important immune reactions responsible for disorders such as neonatal alloimmune thrombocytopenia. Platelets from individuals carrying rare polymorphisms are often difficult to obtain, making diagnostic testing and transfusion of matched platelets challenging. In addition, class I HLA antibodies frequently present in maternal sera interfere with the detection of platelet-reactive alloantibodies. Detection of alloantibodies to human platelet antigen 3 (HPA-3) and HPA-9 is especially challenging, in part because of the presence of cell type-specific glycans situated near the polymorphic amino acid that together form the alloepitope. To overcome these limitations, we generated a series of HLA class I-negative blood group O induced pluripotent stem cell (iPSC) lines that were gene edited to sequentially convert their endogenous HPA-3a alloantigenic epitope to HPA-3b, and HPA-9a to HPA-9b. Subjecting these cell lines, upon differentiation into CD41+/CD42b+ human megakaryocytes (MKs), to flow cytometric detection of suspected anti-HPA-3 and HPA-9 alloantisera revealed that the HPA-3a-positive MKs specifically reacted with HPA-3a patient sera, whereas the HPA-3b MKs lost reactivity with HPA-3a patient sera while acquiring reactivity to HPA-3b patient sera. Importantly, HPA-9b-expressing MKs specifically reacted with anti-HPA-9b-suspected patient samples that had been undetectable using conventional techniques. The provision of specialized iPSC-derived human MKs expressing intact homozygous glycoprotein alloantigens on the cell surface that carry the appropriate endogenous carbohydrate moieties should greatly enhance detection of clinically important and rare HPA-specific alloantibodies that, to date, have resisted detection using current methods.
引用
- Zhang N, Santoso S, Aster RH, et al. Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies. Blood. 2019. PMID: 31697836. doi:10.1182/blood.2019002225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。